| Customization: | Available |
|---|---|
| Dosage Form: | Powder Injection |
| Dossier: | Ready |
|
Still deciding? Get samples of US$ 0.1/Piece
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Generic Name | Cerebrolysin Injcetion 5ml |
| Strength | 5ml |
| Packing | 5ampoules/box |
| Origin | China |
- Primary dementia (e.g. Alzheimer's disease).
- Vascular dementia (e.g., multiple infarct dementia) and cognitive impairment after moderate to mild stroke.
- Mixed dementia.
- Improvement of brain dysfunction after craniocerebral injury.
Usage and dosage:
The recommended course of administration is daily for 10-20 days.
Each course of injection is best continuous, depending on the patient's age and condition to determine the duration of the course and dosage. No more than 2ml for subcutaneous injection, 5ml for intramuscular injection and 10ml for intravenous push injection.
In addition, 10-30ml of this product diluted in 250ml normal saline is recommended for slow infusion, about 60-120 minutes to finish, 10-20 times per course of drug infusion, depending on the condition.
For severe cases, especially those with inadequate cerebrovascular compensation, 10-30ml of Spiroxan diluted in 250ml of normal saline can be used as an infusion. If the drug is administered daily, 10-20 drops should be given per course of treatment. This drug can be used in combination with dextran (e.g., dextran 40), vitamins, and any cardiovascular drug as required. For mild cases or large doses of medication to preserve the efficacy, intravenous injection (or intramuscular injection) can be used once a day, 5ml each time, 10-20 times, 2-3 times a week thereafter, and several courses of treatment can be repeated until the clinical manifestations no longer improve.
Particular attention should be paid to:
- Allergic constitution
- Epileptic states and grand seizure-like convulsions where medication may increase the frequency of seizures.
- Although there is no evidence of renal impairment, this product should not be used in patients with severe renal insufficiency.
- Although clinical studies have not shown the expected slowing of reaction times, impairment of driving and mechanical ability cannot be ruled out and such activities are therefore recommended to be avoided.
Medication for special population:
No reproductive toxicity was found in animal experiments. However, the reproductive toxicity to humans remains unclear. Therefore, for pregnant and lactating women, the use of this drug should weigh the advantages and disadvantages.
Drug interaction:
This drug should not be mixed with a balanced amino acid solution for infusion.
){kind=link}